Morrison & Foerster represented RA Capital and OrbiMed as lead investors in Janux Therapeutics’ $125 million Series B financing. OrbiMed and RA Capital are two of the world’s leading healthcare venture capital firms. Janux Therapeutics is developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. RA Capital and OrbiMed were joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company) and Janux’s existing investors, Avalon Ventures, and Bregua.
MoFo previously represented RA Capital and OrbiMed in Janux’s $56 million Series A financing which closed in March 2021.
The MoFo team was led by San Diego corporate attorneys Jim Krenn, Brennen Brodersen, Andrew Dixon and Carey Hughes.